Search Results
Your search for ,foR matches 32420 pages
Showing 7551 - 7600Expert Point of View: Omid Hamid, MD
Commenting on the SECOMBIT trial was Omid Hamid, MD, Chief of Translational Research and Immunotherapy at The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate, and Co-Director, Cutaneous Malignancy Program, Cedars-Sinai Cancer. Dr. Hamid said SECOMBIT addresses an important...
St. Jude Names Shannon Dean, MD, as Chief Medical Information Officer
Shannon Dean, MD, has joined St. Jude Children’s Research Hospital as Chief Medical Information Officer at a key time in the hospital’s efforts to enhance the patient experience. Dr. Dean will help oversee the launch of the hospital’s new electronic health record, which is scheduled to go live in...
SECOMBIT Trial Evaluates Optimal Treatment Sequencing in BRAF-Mutated Melanoma
Patients with untreated, metastatic BRAF-mutated melanoma may benefit from receiving immunotherapy first, moving to targeted therapy in the second line, data from the updated overall survival analysis of the randomized, phase II SECOMBIT trial suggest.1 The study aimed to define the optimal...
Expert Point of View: Barbara Pistilli, MD
Barbara Pistilli, MD, of the Breast Cancer Group at Gustave Roussy Cancer Center, Villejuif, France, said the results of the TULIP trial, showing the progression-free survival benefit for vic-trastuzumab duocarmazine (SYD985), help to establish antibody-drug conjugates as key components of the...
Another Antibody-Drug Conjugate Enters the Metastatic Breast Cancer Landscape
In the global phase III TULIP trial in metastatic HER2-positive breast cancer, treatment with the antibody-drug conjugate vic-trastuzumab duocarmazine (SYD985) significantly improved progression-free survival in comparison with standard chemotherapy in previously treated patients, making this a new ...
Expert Point of View: Enrique Grande, MD
Invited discussant Enrique Grande, MD, of the Medical Oncology Department at MD Anderson Cancer Center Madrid, said that the VESPER trial should really be regarded as a neoadjuvant trial, since 88% of the patients enrolled were treated in the neoadjuvant setting. He focused the rest of his remarks ...
Neoadjuvant dd-MVAC Improves Local Control and Progression-Free Survival in Patients With Muscle-Invasive Bladder Cancer
The VESPER phase III trial answers some key questions regarding the optimal management of muscle-invasive bladder cancer. The study found that the neoadjuvant regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) was superior to standard gemcitabine/cisplatin in...
Expert Point of View: Johnie Rose, MD, PhD
Invited study discussant, Johnie Rose, MD, PhD, noted that screening is a complex problem that requires balancing the risks of avoidable metastatic prostate cancer with the serious complications associated with treatment. Dr. Rose is Assistant Professor at the Center for Community Health...
Did Change in PSA-Based Screening Recommendation Hinder Prostate Cancer–Specific Survival?
Prostate-specific antigen (PSA) screening recommendations made by the U.S. Preventive Services Task Force (USPSTF) in 2012 may have led to worse outcomes for insured patients with prostate cancer, according to data presented at the 2021 ASCO Quality Care Symposium.1 Findings from the retrospective...
Study Assesses Benefit of Digital Health Tools for Cancer Survivors
New study results suggest that to maximize effects of digital support tools for cancer survivors, it is essential to personalize information and increase engagement efforts. The report, published by Leach et al in the journal Cancer, demonstrated significant improvement in the ability to manage...
Two Studies Examine the Efficacy of Immunotherapy for Leptomeningeal Carcinomatosis
Two new studies published in Nature Communications indicate that immunotherapy may benefit people with leptomeningeal carcinomatosis, a rare but serious complication of cancer that has spread to the brain and/or spinal cord. Approximately 5% to 8% of all patients with cancer develop leptomeningeal ...
National Cancer Act and Lung Cancer Screening: An Example of Intended Impact
The National Cancer Act of 1971 established a national priority to address the widely shared dread of a cancer diagnosis. The goal of the National Cancer Act was to strengthen the National Cancer Institute (NCI) to more effectively carry out the national effort against cancer. After the Act was...
BTK Inhibition in CLL: An Embarrassment of Riches
Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder defined by a specific phenotype and the presence of more than 5,000 clonal B cells in the peripheral blood.1 In the absence of this number of circulating cells, its soft-tissue/bone-marrow counterpart is semantically...
Expert Point of View: Gonzalo Gomez-Abuin, MD, and Gabriel N. Hortobagyi, MD, MACP, FASCO
The invited discussant of the MONALESSA-2 trial was Gonzalo Gomez-Abuin, MD, a medical oncologist who is Head of the Clinical Research Unit at Hospital Alemán in Buenos Aires. According to Dr. Gomez-Abuin, phase III trials of three different CDK4/6 inhibitors—ribociclib, palbociclib, and...
MONALEESA-2: Overall Survival Benefit With First-Line Ribociclib Plus Letrozole
Ribociclib plus hormonal therapy in the first-line setting boosted overall survival by more than 1 year, vs hormone therapy alone, in postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer, according to the latest findings from the MONALEESA-2 trial, reported at...
Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
As reported in The Lancet Oncology by Thierry Facon, MD, and colleagues, an interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to lenalidomide/dexamethasone in newly diagnosed, transplant-ineligible patients with ...
Addition of Liposomal Irinotecan to Fluorouracil and Leucovorin as Second-Line Treatment for Metastatic Biliary Tract Cancer
In a Korean phase IIb trial (NIFTY) reported in The Lancet Oncology, Yoo et al found that the addition of liposomal irinotecan to fluorouracil/leucovorin improved progression-free survival as a second-line treatment for patients with metastatic biliary tract cancer whose disease had progressed on...
Risk-Based Treatment of Pediatric and Young Adult Synovial Sarcoma
In a report from the Children’s Oncology Group ARST0332 study published in the Journal of Clinical Oncology, Venkatamani et al found that risk-based treatment of pediatric and young adult patients with synovial sarcoma produced favorable outcomes in those with nonmetastatic disease. Outcomes in...
Expert Point of View: Joshua K. Sabari, MD
“We know that molecular alterations on gene mutations such as EGFR and ALK can lead to better prognosis, better response rates, and, more important, better quality of life for patients,” said Joshua K. Sabari, MD, of NYU Langone Health Perlmutter Cancer Center, who discussed the abstract at the...
Survey Shows Disparities in Biomarker Testing Among Underserved Patients With Lung Cancer
Recent advances in cancer genomics and targeted therapies have changed the treatment landscape for lung cancer, but disparities in access to precision medicine remain, according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung ...
Activity of Nab-sirolimus in Malignant Perivascular Epithelioid Cell Tumors
In the phase II AMPECT trial reported in the Journal of Clinical Oncology, Wagner et al found that the mTOR inhibitor nab-sirolimus produced a substantial rate of durable responses and a high disease control rate in patients with malignant perivascular epithelioid cell tumors. As stated by the...
Development of a Breast Cancer Risk Prediction Model for Black Women in the United States
As reported in the Journal of Clinical Oncology, Julie R. Palmer, ScD, and colleagues have developed and validated a risk prediction model for invasive breast cancer in Black women in the United States. Study Details For the development of the model, breast cancer relative and attributable risks...
Pharmacovigilance Study of Pancytopenia in Patients Receiving PARP Inhibitors
In a study reported in a research letter in JAMA Oncology, Morice et al found that pancytopenia was associated with use of poly (ADP-ribose) polymerase (PARP) inhibitors for cancer treatment, according to drug adverse event reports in the World Health Organization global pharmacovigilance database...
Patients With Hematologic Malignancies: How Robust Is Their Immunity to SARS–CoV-2?
A large study from the United Kingdom has taken a deep dive into SARS–CoV-2 in the setting of cancer, yielding both concerning and encouraging findings about natural and vaccine-induced immunity. The study was presented at the Presidential Symposium during the European Society for Medical Oncology...
Relationship Between Preexisting TP53 CHIP Variants and Risk of Secondary Myeloid Neoplasms in High-Grade Ovarian Cancer
In a study reported in JAMA Oncology, Kwan et al found that preexisting TP53 clonal hematopoiesis of indeterminate potential (CHIP) variants were associated with increased risk of secondary myeloid neoplasms in patients receiving poly (ADP-ribose) polymerase (PARP) inhibitor therapy with rucaparib...
Do Patients Diagnosed With Cancer Living in Low-Income and Rural Areas Face an Increased Risk of Suicide?
Individuals diagnosed with cancer who live in low-income and rural areas may face an increased risk of suicide compared with patients living in high-income and urban areas, according to a study published by Suk et al in JAMA Network Open. The research focused on determining whether the risks and...
Study Examines Opinions on Telemedicine Among Patients Undergoing Radiotherapy
New research published by Shaverdian et al in JNCCN—Journal of the National Comprehensive Cancer Network assessed patient satisfaction and preferences associated with telemedicine. Researchers found 45% of people with cancer undergoing radiotherapy preferred telemedicine, whereas 34% preferred...
Mobocertinib for Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic NSCLC
In a phase I/II trial reported in JAMA Oncology, Caicun Zhou, PhD, MD, and colleagues found that mobocertinib, a first-in-class oral kinase inhibitor, produced durable responses in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer (NSCLC). The...
Nivolumab/Low-Dose Ipilimumab Produces Responses in Patients With MSI-H/dMMR Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Heinz-Josef Lenz, MD, and colleagues, in the phase II CheckMate 142 trial, first-line treatment with nivolumab plus low-dose ipilimumab produced a high rate of durable responses in a cohort of patients who had received no prior treatment for...
Efficacy of Quadrivalent HPV Vaccine in Girls in India Against Persistent HPV-16/18 Infection: 10-Year Protection Analysis
In a prospective cohort study reported in The Lancet Oncology, Partha Basu, MD, and colleagues found that a single dose of quadrivalent human papillomavirus (HPV) vaccine given to girls in India provided 10-year protection equal to two or three doses against persistent infection with HPV types 16...
Susana N. Banerjee, MBBS, PhD, on Ovarian Cancer: Novel Combination Therapy Under Study
Susana N. Banerjee, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase I results that have generated interest in the combination of the RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib for patients with recurrent low-grade serous ovarian cancer, a disease that typically ...
Susana N. Banerjee, MBBS, PhD, on Ovarian, Fallopian Tube, or Primary Peritoneal Adenocarcinoma: Treatment Findings From the EORTC-1508 Trial
Susana N. Banerjee, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase II results of the EORTC-1508 trial, the first study to combine an anti–PD-L1 antibody, atezolizumab, with bevacizumab and the COX1/2 inhibitor acetylsalicylic acid as treatment for patients with ovarian,...
Dieter Hörsch, MD: For Patients With Bronchopulmonary Neuroendocrine Tumors, Lanreotide Autogel May Be Beneficial
Dieter Hörsch, MD, of Germany’s Central Clinic in Bad Berka, discusses phase III results from the SPINET trial, the largest prospective study to date of the somatostatin analog lanreotide autogel. The study suggests that this agent may prove to be an appropriate treatment option for patients with...
Expert Point of View: Clare L. Scott, MBBS, PhD
Invited discussant Clare L. Scott, MBBS, PhD, Chair of Gynaecological Cancer at the University of Melbourne and medical oncologist at Peter MacCallum Cancer Centre, Melbourne, Australia, said: “We now know that PARP [poly (ADP-ribose) polymerase] inhibitors are active post PARP therapy. We also...
PARP Rechallenge Slows Ovarian Cancer Progression in Platinum-Sensitive Disease
Rechallenge with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in patients with platinum-sensitive ovarian cancer led to significant improvement in progression-free survival, in patients with either BRCA1/2-mutated or nonmutated (ie, wild-type) disease compared with placebo, according ...
Preclinical Study Examines Relationship Between Aging Breast Tissue and Invasive Breast Cancer
Breast cancer risk increases with age, but while scientists have long studied cellular changes that take place in the body over time, a new study published by Bahcecioglu et al in Advanced Science examined how the extracellular matrix—an underlying network of molecules and proteins that provide the ...
Primary Tumor Resection Followed by Systemic Treatment vs Systemic Treatment Alone in Metastatic Colorectal Cancer: 60-Day Mortality
As reported in JAMA Surgery by van der Kruijssen et al, 60-day post–random assignment mortality results in the Danish/Dutch phase III CAIRO4 trial showed higher rates of mortality in patients with metastatic colorectal cancer who received primary tumor resection plus systemic treatment vs those...
First-Line Fulvestrant/Palbociclib vs Letrozole/Palbociclib for Endocrine-Sensitive, HR-Positive, HER2-Negative Advanced Breast Cancer
In the phase II PARSIFAL trial reported in JAMA Oncology, Antonio Llombart-Cussac, MD, and colleagues found that the combination of fulvestrant plus palbociclib did not improve progression-free survival vs letrozole plus palbociclib in women with advanced endocrine-sensitive, hormone receptor...
Global Analysis of National Health System Characteristics and Breast Cancer Mortality and Stage at Diagnosis
In a global population-based study reported in The Lancet Oncology, Duggan et al identified national health system characteristics associated with reduced breast cancer mortality, including higher Universal Health Coverage Service Coverage Index (UHC Index) rating and increased number of public...
Ibrutinib vs Placebo Following Achievement of Undetectable MRD With First-Line Ibrutinib/Venetoclax in CLL
As reported in the Journal of Clinical Oncology by William G. Wierda, MD, PhD, and colleagues, findings in the measurable residual disease (MRD) cohort of the phase II CAPTIVATE study indicated a high disease-free survival rate with placebo and no significant benefit of continued ibrutinib in...
Second-Line Sotorasib Plus Afatinib for KRAS-Mutant NSCLC
The combination of the KRAS inhibitor sotorasib with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating patients with non–small cell lung cancer (NSCLC) and mutated KRAS whose disease had progressed on prior therapies, including KRAS inhibitors alone, according to interim...
DM-CHOC-PEN May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors
In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young adult patients with cancers involving the central nervous system, according to results presented by Morgan et al at the AACR-NCI-EORTC Virtual...
Can Inhibition of the Aurora Kinase A Protein Help Overcome Resistance to KRAS Inhibition in Patients With Lung Cancer?
In preclinical models, combining an investigational Aurora kinase A (AURKA) inhibitor with a KRAS inhibitor or a WEE1 inhibitor showed efficacy against lung cancer cells with intrinsic or acquired resistance to KRAS inhibition, according to results presented by Lee et al at the AACR-NCI-EORTC...
FDA Perspective on Drug-Dosing in Oncology: From ‘More Is Better’ to ‘Less Can Be More’
In a perspective article published in The New England Journal of Medicine entitled “The Drug-Dosing Conundrum in Oncology—When Less Is More,” four authors from the U.S. Food and Drug Administration (FDA) argue for the need to jettison the “more is better” paradigm in dose selection for oncology...
Abiraterone for Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer
In an Italian single-institution phase II trial reported in the Journal of Clinical Oncology, Locati et al found that abiraterone acetate showed activity in patients with androgen deprivation therapy (ADT)-resistant, androgen receptor (AR)-overexpressing salivary gland carcinoma. As stated by the...
Final Analysis of iNNOVATE: Addition of Ibrutinib to Rituximab for Waldenström’s Macroglobulinemia
As reported in the Journal of Clinical Oncology by Buske et al, the final analysis of the pivotal phase III iNNOVATE trial has shown a continued progression-free survival benefit with the addition of ibrutinib to rituximab in patients with Waldenström’s macroglobulinemia after 50 months of...
FDA Approvals in Breast and Cervical Cancers
This week, the FDA approved new indications for two drugs. The first approval was for abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast...
Nodal Recurrence With Sentinel Node Biopsy Alone Following Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
In a single-center cohort study reported in JAMA Oncology, Barrio et al evaluated nodal recurrence rates in patients with clinically node-negative breast cancer following neoadjuvant chemotherapy for biopsy-proven node-positive disease. The investigators found an extremely low incidence of nodal...
Study Examines Potential Link Between Cancer and Physical Inactivity
A new report finds that more than 46,000 cancer cases annually in the United States could be prevented if Americans met the 5 hours per week of moderate-intensity activity recommended in the American Cancer Society’s physical activity guidelines. Recent findings published by Minihan et al in the...
FDA Approves Atezolizumab as Adjuvant Treatment for NSCLC
On October 15, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as...
